MSB 4.39% $1.09 mesoblast limited

2024 Here we go again., page-397

  1. 1,676 Posts.
    lightbulb Created with Sketch. 178
    Are the "other outstanding items" you mention a reference to this last sentence in the recent ann?

    "Mesoblast intends to file the resubmission during the next quarter, seeking to address all remaining product characterization issues."

    If so I believe "characterization" is a reference to the assay matrix queries from FDA.
    The question is why not be specific instead of calling it "clinical data" earlier in the ann given efficacy wasn't an issue, if indeed as I believe they mean assayed samples when they referenced "clinical data".

    Cheers.
 
watchlist Created with Sketch. Add MSB (ASX) to my watchlist
(20min delay)
Last
$1.09
Change
-0.050(4.39%)
Mkt cap ! $1.244B
Open High Low Value Volume
$1.14 $1.17 $1.07 $8.385M 7.489M

Buyers (Bids)

No. Vol. Price($)
1 8500 $1.08
 

Sellers (Offers)

Price($) Vol. No.
$1.09 26954 3
View Market Depth
Last trade - 16.10pm 19/06/2024 (20 minute delay) ?
MSB (ASX) Chart
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.